A team in Sydney has built a nanoparticle that does two things a glioblastoma surgeon badly needs, and does them with the same beam of light: it makes microscopic tumor clusters glow during the operation, then destroys what the scalpel could not reach afterward. In mice, every treated animal survived to the 60-day mark. In humans, it has not been tried at all.
Why Glioblastoma Keeps Coming Back
Glioblastoma is the most aggressive form of brain cancer, and the reason it is so hard to cure has less to do with the tumor a surgeon can see than with the cells a surgeon cannot. Glioblastoma cells infiltrate the surrounding brain tissue in fingers and threads, so a complete removal would mean cutting away healthy brain that the patient needs. The blood-brain barrier compounds the problem by limiting how much of any drug actually reaches the tumor bed. Together these two obstacles help explain a five-year survival rate of only about 7 percent.[1]
A Single Material That Switches Roles
A team at the University of Technology Sydney, working with collaborators at Harvard and Henan University, has built what they describe as a double-punch nanozyme platform, published in Science Translational Medicine.[2] The design starts from an extremely thin two-dimensional sheet studded with individual metal atoms placed one at a time using a technique borrowed from semiconductor manufacturing. What makes the platform unusual is that it does not do one job well; it does two jobs in sequence, and both are triggered by the same wavelength of near-infrared light. Lead researcher Bingyang Shi described it as a precise guide for the surgeon during the operation, and then a targeted clean-up treatment afterward.[1]
Seeing Tumor Clusters 44 Micrometers Wide
In its first role, the material behaves as an imaging agent. A fluorescent dye engineered onto the sheet glows under near-infrared light that is invisible to the naked eye, and the researchers report that this allowed them to distinguish tumor cell clusters as small as 44 micrometers, a resolution finer than what current clinical imaging tools deliver.[1] A targeting molecule attached to the sheet helps it cross the blood-brain barrier and concentrate in glioma cells rather than in healthy tissue. In practical terms, the ambition is to let a surgeon see the edge of the disease rather than infer it.
Turning the Tumor Chemistry Against Itself
The second role begins after the visible tumor has been removed. The same material is placed into the surgical cavity and re-illuminated with the same wavelength. Platinum atoms on the sheet convert hydrogen peroxide produced by the tumor into oxygen, which counteracts the low-oxygen environment that ordinarily shields cancer cells from treatment, while the light simultaneously generates heat and reactive molecules that damage the microscopic cancer cells surgery could not reach.[1] It is a neat piece of design logic: the condition that normally protects residual tumor becomes the fuel for destroying it.
What the Survival Numbers Actually Say
In mouse models of glioblastoma, the approach reduced tumor recurrence after surgery. Every treated mouse was still alive at 60 days, compared with a survival of 42 days in animals that received surgery alone.[1] Follow-up testing found no detectable neurological or motor impairment associated with the treatment. Those are strong preclinical numbers, but it is worth being precise about what they mean: 100 percent survival at a fixed 60-day checkpoint in a rodent model is an encouraging signal about recurrence, not a statement about how long a human patient would live.
The Distance Between a Mouse Brain and a Human One
The researchers themselves draw the line clearly. Shi noted that the results are encouraging but that this is still early-stage research carried out in mouse models, not in people, and that the imaging and therapeutic performance will need to be confirmed at the scale of a human brain.[1] That scale question is not a formality. Near-infrared light penetrates tissue only so far, and a human resection cavity is far larger and more geometrically complex than a mouse one. Manufacturing single-atom sheets reproducibly at clinical volume, and clearing the regulatory path for a material that is both a contrast agent and a therapeutic, are separate hurdles again.
What Would Make This Real
The useful thing to watch is not the next press release but the next set of experiments: whether the platform works in larger animal brains, whether the light dose needed to activate it in a human-sized cavity remains safe, and whether the nanozyme clears from the body without long-term deposition. Theranostic agents that combine diagnosis and therapy have a long history of impressive animal data and difficult translation. If this one holds up, the practical payoff would be narrow but meaningful: fewer cells left behind at the moment of surgery, and therefore a later recurrence, which for glioblastoma patients is currently where most of the achievable benefit lies.
| Aspect | Finding |
|---|---|
| Study type | Preclinical study in mouse models of glioblastoma; no human testing to date |
| Institutions | University of Technology Sydney, with Harvard and Henan University collaborators |
| Platform | Two-dimensional single-atom nanozyme sheet, activated by near-infrared light |
| Imaging resolution | Tumor cell clusters as small as 44 micrometers |
| Therapeutic mechanism | Platinum atoms convert tumor hydrogen peroxide into oxygen; light generates heat and reactive molecules |
| Survival result | All treated mice alive at 60 days vs. 42 days survival with surgery alone |
| Safety signal | No detectable neurological or motor impairment in follow-up testing |
| Context | Glioblastoma five-year survival is approximately 7 percent |
| Main limitation | Performance must still be confirmed at the scale of a human brain |
References
- University of Technology Sydney, “Smart nanoparticles light up brain cancer and destroy what surgery misses,” via ScienceDaily, August 27, 2026.
- Shangguan P, Zhong Y, Wu H, et al. “Spatiotemporal-switchable 2D NIR-II single-atom nanozyme for single-cell-level surgical navigation and glioblastoma phototherapy.” Science Translational Medicine, 2026;18(861). DOI: 10.1126/scitranslmed.aeb8054
